Giovanni cafio brystol myers email5/29/2023 Angiolillo reports receiving payments as an individual for: (a) Consulting fee or honorarium from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Janssen, Merck, PLx Pharma, Pfizer, Sanofi, and The Medicines Company (b) participation in review activities from CeloNova and St. Cattaneo reports receiving payments for consulting fee or honorarium from AstraZeneca, Merck, Eli Lilly, Daiichi Sankyo.ĭr. Somaschini have no conflict of interest to report.ĭr. The GEPRESS study was supported by a research grant from Eli Lilly and Daiichi Sankyo.ĭr. This is the first study showing that residual HPR is more likely to occur in patients with CRP >1 mg/L at 1 month after non-ST elevation-ACS and this may contribute to the unfavorable outcome observed in such patients. After adjustment for covariates, we found a direct gradient of effect between CRP and HPR the inclusion of CRP significantly increased the discrimination of HPR regression model. Of the 1042 patients included in the GEPRESS study, 756 (75%) had both VASP and CRP data at 30 days follow-up. PRI was assessed with vasodilator stimulated phosphoprotein (VASP) phosphorylation assay at the same timepoint. We measured CRP and platelet reactivity index (PRI) at 30 days follow-up. We aimed to evaluate the impact of 1-month C-reactive Protein (CRP) levels on HPR in patients enrolled in the GEPRESS study. Inflammation could be linked to high platelet reactivity (HPR), which is an independent predictor of MACE in patients with ACS. ![]() Recent clinical trials targeting CPR showed a reduction in MACE after an acute coronary syndrome (ACS). Systemic inflammation measured by high-sensitivity C reactive protein (CPR) is associated with increased risk of major adverse cardiovascular events (MACE).
0 Comments
Leave a Reply. |